Application of 3-phenyl lactate or fermentation product containing 3-phenyl lactate in preparation of skin care product and skin care product

By combining 3-phenyl lactic acid with alcohol or sugar molecules to form ester compounds, the problems of 3-phenyl lactic acid in skin care products are solved, and significant antioxidant and skin repair effects are achieved, delaying skin aging.

CN120114342APending Publication Date: 2025-06-10SHANDONG SAKRUIDE BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202510306004.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-03-14
Publication Date
2025-06-10

AI Technical Summary

Technical Problem

The existing application of 3-phenyl lactic acid in skin care products has problems such as skin irritability, low water solubility and poor compatibility, which makes it difficult to effectively antioxidant and delay skin aging.

Method used

Using 3-phenyl lactate or fermentation products containing 3-phenyl lactate, the application performance of the esters in skin care products is improved by forming ester compounds with C1-C30 alcohols or sugar molecules.

Benefits of technology

3-phenyl lactate significantly enhances the antioxidant ability of keratinocytes and promotes cell proliferation, improves the synthesis of collagen and the expression of mitochondrial respiratory chain complexes in fibroblasts, and can effectively reduce skin aging and promote skin damage repair.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005312965520000071
    Figure BDA0005312965520000071
  • Figure BDA0005312965520000081
    Figure BDA0005312965520000081
  • Figure BDA0005312965520000091
    Figure BDA0005312965520000091
Patent Text Reader

Abstract

The invention relates to the technical field of cosmetics, in particular to application of 3-phenyl lactate or a fermentation product containing the 3-phenyl lactate in preparation of a skin care product and the skin care product. According to the application disclosed by the invention, an in-vitro cell model is adopted for carrying out a function test on 3-phenyl lactate, and in a keratinocyte model, the 3-phenyl lactic acid monoglyceride has a remarkable anti-oxidation effect and a remarkable cell proliferation promoting capability, so that oxidative stress injury can be reduced, and epidermis repair and regeneration can be promoted; in a fibroblast model, the 3-phenyl lactic acid monoglyceride remarkably promotes collagen expression, enhances expression of SKN-1 and ATFS-1 signal channel related genes and mitochondrial respiratory chain complex II and V related genes, and can enhance the cell oxidation resistance, improve the energy metabolism efficiency and promote protein synthesis and repair, so that the fibroblast has the advantages that the fibroblast has a good application prospect. Skin elasticity can be improved, skin aging can be relieved, and skin injury repair can be promoted.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of cosmetics, and particularly to the application of 3-phenyllactate or a fermentation product containing 3-phenyllactate in the preparation of skin care products and a skin care product. Background Art

[0002] Disclosing the information of this background art section is only intended to enhance the understanding of the overall background of the present invention, and is not necessarily to be regarded as an admission or any form of implication that this information constitutes the prior art already known to those of ordinary skill in the art.

[0003] 3-Phenyllactic acid, also known as phenyllactic acid or β-phenyllactic acid, can be obtained by chemical synthesis or biological fermentation. Currently, the main research directions of 3-phenyllactic acid are microbial inhibitors, preservatives, and biodegradable polymers, and there are relatively few studies on other application directions. Reports in the field of skin care only show moisturizing and treating skin dryness. However, there are some risks in applying 3-phenyllactic acid to the skin, including skin irritation caused by 3-phenyllactic acid as a lactic acid structural analogue, low water solubility, and poor compatibility with ingredients such as carbomer after being an acidic component or forming a salt.

[0004] Cells are the largest organs in the human body, and human aging can to some extent be said to be cell aging. During skin aging, along with the aging of keratinocytes and fibroblasts, the epidermis becomes thinner and of poorer quality, the collagen and elastin in the dermis decrease, and the skin shows wrinkle proliferation and loss of elasticity.

[0005] Therefore, developing a skin care product with low skin irritation, good absorbability, good compatibility with ingredients, and having antioxidant and anti-skin-aging effects will have good market prospects. Summary of the Invention

[0006] In order to overcome the above problems, the present invention provides the application of 3-phenyllactate or a fermentation product containing 3-phenyllactate in the preparation of skin care products and a skin care product.

[0007] To achieve the above technical purpose, the present invention adopts the following technical solutions:

[0008] In the first aspect of the present invention, there is provided the application of 3-phenyllactate or a fermentation product containing 3-phenyllactate in the preparation of skin care products;

[0009] The 3-phenyllactate includes ester compounds formed by 3-phenyllactic acid and C1-C30 alcohols and ester compounds formed by 3-phenyllactic acid and sugar molecules.

[0010] In one or more embodiments, the C1-C30 alcohol is selected from linear or branched C1-C30 aliphatic monohydric or polyhydric alcohols, preferably linear or branched C2-C30 aliphatic monohydric or polyhydric alcohols, more preferably 1,2-propanediol, 1,3-propanediol, glycerol, 1,3-butanediol and 1,2-butanediol, and even more preferably glycerol.

[0011] In one or more embodiments, the saccharide molecule is a hydrogenated saccharide molecule, preferably inositol, sorbitol, mannitol, erythritol and xylitol.

[0012] In one or more embodiments, the 3-phenyllactic acid is selected from one or more of D-3-phenyllactic acid, L-3-phenyllactic acid and DL-phenyllactic acid.

[0013] In one or more embodiments, the application includes any one of the following:

[0014] A1) Application of 3-phenyllactate or a fermentation product containing 3-phenyllactate in enhancing the antioxidant capacity of keratinocytes;

[0015] A2) Application of 3-phenyllactate or a fermentation product containing 3-phenyllactate in the preparation of a product for enhancing the antioxidant capacity of keratinocytes;

[0016] A3) Application of 3-phenyllactate or a fermentation product containing 3-phenyllactate in promoting the proliferation of keratinocytes;

[0017] A4) Application of 3-phenyllactate or a fermentation product containing 3-phenyllactate in the preparation of a product for promoting the proliferation of keratinocytes.

[0018] In one or more embodiments, the application includes any one of the following:

[0019] B1) Application of 3-phenyllactate or a fermentation product containing 3-phenyllactate in enhancing the synthesis of collagen in fibroblasts;

[0020] B2) Application of 3-phenyllactate or a fermentation product containing 3-phenyllactate in the preparation of a product for enhancing the synthesis of collagen in fibroblasts;

[0021] B3) Use of 3-phenyllactate or a fermentation product containing 3-phenyllactate in enhancing the expression of genes related to SKN-1 and ATFS-1 signaling pathways in fibroblasts; the genes related to SKN-1 and ATFS-1 signaling pathways include: glutathione S-transferase 1 (GST-1), superoxide dismutase 3 (SOD3), heat shock protein 6 (HSP6), dynein axonemal heavy chain 11 (DNAH-11), activating transcription factor 3 (ATF3);

[0022] B4) Use of 3-phenyllactate or a fermentation product containing 3-phenyllactate in the preparation of a product for enhancing the expression of genes related to SKN-1 and ATFS-1 signaling pathways in fibroblasts; the genes related to SKN-1 and ATFS-1 signaling pathways include: glutathione S-transferase 1 (GST-1), superoxide dismutase 3 (SOD3), heat shock protein 6 (HSP6), dynein axonemal heavy chain 11 (DNAH-11), activating transcription factor 3 (ATF3);

[0023] B5) Use of 3-phenyllactate or a fermentation product containing 3-phenyllactate in enhancing the expression of genes related to mitochondrial respiratory chain complexes II and V in fibroblasts; the genes related to mitochondrial respiratory chain complexes II and V include: succinate dehydrogenase complex subunit A (SDHA), succinate dehydrogenase complex subunit B (SDHB), ATP synthase subunit α (ATP5A), ATP synthase subunit β (ATP5B), mitochondrial ribosomal protein L23 (MRPL23), mitochondrial ribosomal protein S3 (MRPS3);

[0024] B6) Use of 3-phenyllactate or a fermentation product containing 3-phenyllactate in the preparation of a product for enhancing the expression of genes related to mitochondrial respiratory chain complexes II and V in fibroblasts; the genes related to mitochondrial respiratory chain complexes II and V include: succinate dehydrogenase complex subunit A (SDHA), succinate dehydrogenase complex subunit B (SDHB), ATP synthase subunit α (ATP5A), ATP synthase subunit β (ATP5B), mitochondrial ribosomal protein L23 (MRPL23), mitochondrial ribosomal protein S3 (MRPS3).

[0025] In a second aspect of the present invention, there is provided a skin care product comprising 3-phenyllactate or a fermentation product containing 3-phenyllactate in the first aspect.

[0026] In one or more embodiments, the skin care product comprises at least one of lotion, emulsion, essence, serum, mask, sunscreen, cream, eye cream, hand cream or body lotion.

[0027] Preferably, the facial mask is a patch facial mask or a smear facial mask.

[0028] Preferably, the essence is essence water, essence oil or essence gel.

[0029] In one or more embodiments, the skin care product further comprises a cosmetically acceptable excipient.

[0030] Preferably, the excipient is one or more of a solvent, a thickening agent, a humectant, a film-forming agent, a liposome, a preservative, a colorant, a pH regulator and a fragrance.

[0031] Preferably, the solvent is water or an alcohol solvent.

[0032] The beneficial effects of the present invention are as follows:

[0033] The present invention relates to the technical field of cosmetics, and specifically relates to the application of 3-phenyllactate or a fermentation product containing 3-phenyllactate in the preparation of a skin care product and a skin care product. In the present invention, an in vitro cell model is used for the functional test of 3-phenyllactate. In the keratinocyte model, 3-phenyllactic acid monoglyceride has significant antioxidant effects and the ability to promote cell proliferation, indicating that it can reduce oxidative stress damage and promote epidermal repair and regeneration; in the fibroblast model, 3-phenyllactic acid monoglyceride significantly promotes collagen expression, enhances the expression of genes related to the SKN-1 and ATFS-1 signaling pathways, and genes related to mitochondrial respiratory chain complexes II and V, and can enhance the cell antioxidant capacity, improve the energy metabolism efficiency, and promote protein synthesis and repair. It is shown that it can improve skin elasticity, reduce skin aging, and promote skin damage repair. Therefore, 3-phenyllactic acid monoglyceride or a fermentation broth containing 3-phenyllactic acid monoglyceride can be added to skin care products as a skin care active ingredient to provide functionality for skin care products. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] The specification drawings forming a part of the present invention are used to provide a further understanding of the present invention. The schematic embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute an improper limitation to the present invention.

[0035] Figure 1 It is an image of keratinocytes after culturing with 3-phenyllactic acid monoglyceride in the medium in Example 1 for 24 hours; among them, the concentrations of 3-phenyllactic acid monoglyceride in a-g are 0, 10, 20, 40, 60, 80, 100 μM respectively. DETAILED DESCRIPTION OF THE EMBODIMENTS

[0036] It should be noted that the following detailed description is exemplary and is intended to provide further explanation of the present invention. Unless otherwise specified, all technical and scientific terms used in the present invention have the same meaning as commonly understood by those of ordinary skill in the technical field to which the present invention pertains.

[0037] It should be noted that the terms used herein are only for describing specific embodiments and are not intended to limit the exemplary embodiments according to the present invention. As used herein, unless the context clearly indicates otherwise, the singular forms are also intended to include the plural forms. In addition, it should be understood that when the terms "comprising" and / or "including" are used in this specification, they indicate the presence of features, steps, operations, devices, components, and / or combinations thereof.

[0038] In order to enable those skilled in the art to more clearly understand the technical solution of the present invention, the technical solution of the present invention will be described in detail below in conjunction with specific embodiments.

[0039] Example 1

[0040] Synthesis of monoglyceryl 3-phenyllactate:

[0041] 3-Phenyllactic acid (Merck, P7251) and glycerol (analytical grade) were mixed in a molar ratio of 1:1.5 with glycerol in excess. p-Toluenesulfonic acid was added as a catalyst in an amount of 5.0% of the molar amount of 3-phenyllactic acid. The reaction was stirred at 100 - 110 °C for 3 h. During the reaction, the water generated during the reaction was removed through a water separator installed on the flask. After the reaction was completed, the reaction mixture was cooled and an equal volume of saturated sodium bicarbonate solution was added to neutralize the reactants. Ethyl acetate with a volume equal to that of the mixture was added, and the product was extracted by shaking, and this was repeated 2 times. The ethyl acetate phases were combined. The ethyl acetate phase was washed with saturated brine with an equal volume of ethyl acetate, and this was repeated 2 times. A small amount of anhydrous sodium sulfate was added to the ethyl acetate phase to adsorb water, and the sodium sulfate was removed by filtration. Ethyl acetate was evaporated using a rotary evaporator at a water bath temperature of 30 - 40 °C and a vacuum of 100 - 200 mbar to obtain monoglyceryl 3-phenyllactate. LC-MS (m / z): 240.10 (100.0%), 241.18 (14.2%), 242.06 (1.1%), which was confirmed to be monoglyceryl 3-phenyllactate.

[0042] Example 2

[0043] Synthesis of a fermentation product containing monoglyceryl 3-phenyllactate:

[0044] ​Using the Lactobacillus brevis strain Lactobacillus brevis ATCC14869 capable of producing 3-phenyllactic acid, inoculate the Lactobacillus brevis strain into MRS liquid medium, anaerobically ferment at 37 °C for 24 h until the stationary phase, add 5% W / W glycerol, and adjust the pH of the fermentation broth to within the range of 5.0 - 5.5. Add the Saccharomyces cerevisiae strain (using the esterase activity of yeast to catalyze the production of 3-phenyllactic acid glycerol ester), and the inoculum size is 1E 7 ~1E 8 CFU / mL. Control the fermentation parameters as temperature 28 - 32 °C, pH 5.0 - 5.5, stir but do not aerate. After 24 h of fermentation, centrifuge to remove the cells, and filter the supernatant through a 0.22 μm filter membrane to obtain the fermentation filtrate. HPLC detection shows that the content of 3-phenyllactic acid monoglyceride in the fermentation filtrate is 0.18% w / w. The fermentation filtrate can be used as an active substance containing 3-phenyllactic acid monoglyceride, or an organic solvent extraction can be referred to Example 1 to obtain a fermentation product with a higher concentration of 3-phenyllactic acid monoglyceride.

[0045] Example 3

[0046] Effect of 3-phenyllactic acid monoglyceride on human keratinocytes:

[0047] In this example, the 3-phenyllactic acid monoglyceride synthesized in Example 1 is used.

[0048] Cell culture: Using the human keratinocyte cell line HaCaT, the medium is DMEM containing 10% fetal bovine serum (FBS), and the culture conditions are 37 °C, 5% CO 2 .

[0049] Treatment with 3-phenyllactic acid monoglyceride: Group the HaCaT cells, add different concentrations of 3-phenyllactic acid monoglyceride (0, 10, 20, 40, 60, 80, 100 μM) to the medium and continue to culture for 24 hours. After culturing, centrifuge to remove the culture solution, add 200 μL of phosphate buffer with a pH of 7.0 to each well, ultrasonically bath at room temperature for 30 seconds with a 30-second interval and cycle 5 times to break the cells, centrifuge, and take the supernatant to detect the antioxidant capacity. The antioxidant capacity is measured by DPPH free radical scavenging assay and superoxide dismutase (SOD) activity detection kit (Solarbio BC0175) respectively. Another group of cells cultured with different concentrations of 3-phenyllactic acid monoglyceride for 24 h is taken, and the cell proliferation is detected using the CCK-8 kit (Beyotime C0038). The images of keratinocytes after culturing are shown in Figure 1 .

[0050] As shown in Table 1 of the experimental results.

[0051] Table 1 Effects of different concentrations of 3-phenyllactic acid monoglyceride on the antioxidant capacity and cell proliferation of keratinocytes

[0052]

[0053] As can be seen from the results in Table 1, after treatment with monoglyceryl 3-phenyllactate, the scavenging rate of intracellular contents on DPPH free radicals was significantly increased and showed concentration dependence, and the intracellular SOD activity was significantly increased, indicating that monoglyceryl 3-phenyllactate can enhance the antioxidant capacity of keratinocytes and reduce oxidative stress damage. The treatment with monoglyceryl 3-phenyllactate could significantly increase the cell proliferation rate compared with the control group, and showed concentration dependence in the concentration range of 10-60 μM. Continuing to increase the concentration of monoglyceryl 3-phenyllactate, the increase rate of the proliferation rate slowed down. The above results indicate that monoglyceryl 3-phenyllactate has significant antioxidant effects and the ability to promote cell proliferation, and can reduce oxidative stress damage and promote epidermal repair and regeneration.

[0054] Example 4

[0055] Effect of monoglyceryl 3-phenyllactate on fibroblasts:

[0056] In this example, monoglyceryl 3-phenyllactate synthesized in Example 1 was used.

[0057] Human dermal fibroblasts (HDF) were cultured in DMEM containing 10% fetal bovine serum (FBS) at 37 °C and 5% CO 2 ₂. Cells were seeded in 6-well plates. After growing to 70-80% confluence, they were treated with 0 μM (control group), 20 μM and 40 μM of monoglyceryl 3-phenyllactate for 24 hours. Quantitative analysis of the expression of the following genes was performed by qt-rPCR: alpha-1 chain of type I collagen (COL1A1), alpha-1 chain of type III collagen (COL3A1), glutathione S-transferase 1 (GST-1), superoxide dismutase 3 (SOD3), heat shock protein 6 (HSP6), dynein axonemal heavy chain 11 (DNAH-11), activating transcription factor 3 (ATF3), succinate dehydrogenase complex subunit A (SDHA), succinate dehydrogenase complex subunit B (SDHB), ATP synthase subunit alpha (ATP5A), ATP synthase subunit beta (ATP5B), mitochondrial ribosomal protein L23 (MRPL23), mitochondrial ribosomal protein S3 (MRPS3). Using GAPDH as the internal reference gene, the relative gene expression levels were calculated by the 2-ΔΔCt method, and the results are shown in Table 2.

[0058] Table 2 Effects of monoglyceryl 3-phenyllactate on gene expression in fibroblasts

[0059]

[0060]

[0061] As can be seen from Table 2, monoglyceryl 3-phenyllactate significantly promoted the expression of collagen and enhanced the expression of genes related to the SKN-1 and ATFS-1 signaling pathways, as well as genes related to mitochondrial respiratory chain complexes II and V; it can enhance the antioxidant capacity of cells, improve the energy metabolism efficiency, and promote protein synthesis and repair. It is shown that it can improve skin elasticity, reduce skin aging, and promote skin injury repair.

[0062] The above are only the preferred embodiments of the present invention and are not intended to limit the present invention. For those skilled in the art, various modifications and changes can be made to the present invention. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included within the protection scope of the present invention.

Claims

1. Use of 3-phenyl lactate or a fermentation product containing 3-phenyl lactate in the preparation of skin care products; The 3-phenyl lactic acid esters include ester compounds formed by 3-phenyl lactic acid and C1-C30 alcohols and ester compounds formed by 3-phenyl lactic acid and sugar molecules.

2. The use according to claim 1, characterized in that The C1-C30 alcohol is selected from linear or branched C1-C30 aliphatic monohydric alcohol or polyhydric alcohol, preferably linear or branched C2-C80 aliphatic monohydric alcohol or polyhydric alcohol, more preferably 1,2-propylene glycol, 1,3-propylene glycol, glycerol, 1,3-butylene glycol and 1,2-butylene glycol, and even more preferably glycerol.

3. The use according to claim 1, characterized in that The sugar molecules are hydrogenated sugar molecules, preferably inositol, sorbitol, mannitol, erythritol and xylitol.

4. The use according to claim 1, characterized in that The 3-phenyllactic acid is selected from one or more of D-3-phenyllactic acid, L-3-phenyllactic acid and DL-phenyllactic acid.

5. The use according to claim 1, characterized in that The application includes any of the following: A1) Use of 3-phenyllactate or a fermentation product containing 3-phenyllactate for improving the antioxidant capacity of keratinocytes; A2) Use of 3-phenyllactate or a fermentation product containing 3-phenyllactate in the preparation of a product for improving the antioxidant capacity of keratinocytes; A3) Use of 3-phenyllactate or a fermentation product containing 3-phenyllactate in promoting keratinocyte proliferation; A4) Use of 3-phenyllactate or a fermentation product containing 3-phenyllactate in the preparation of a product for promoting keratinocyte proliferation.

6. The use according to claim 1, characterized in that The application includes any of the following: B1) Use of 3-phenyllactate or a fermentation product containing 3-phenyllactate for increasing collagen synthesis in fibroblasts; B2) Use of 3-phenyllactate or a fermentation product containing 3-phenyllactate in the preparation of a product for increasing collagen synthesis in fibroblasts; B3) Use of 3-phenyllactate or a fermentation product containing 3-phenyllactate in enhancing the expression of genes related to SKN-1 and ATFS-1 signaling pathways in fibroblasts; the genes related to SKN-1 and ATFS-1 signaling pathways include: glutathione S transferase 1 (GST-1), superoxide dismutase 3 (SOD3), heat shock protein 6 (HSP6), dynein axoneme heavy chain 11 (DNAH-11), activating transcription factor 3 (ATF3); B4) Use of 3-phenyllactate or a fermentation product containing 3-phenyllactate in the preparation of a product for enhancing the expression of genes related to SKN-1 and ATFS-1 signaling pathways in fibroblasts; the genes related to the SKN-1 and ATFS-1 signaling pathways include: glutathione S transferase 1 (GST-1), superoxide dismutase 3 (SOD3), heat shock protein 6 (HSP6), dynein axoneme heavy chain 11 (DNAH-11), and activating transcription factor 3 (ATF3); B5) Use of 3-phenyllactate or a fermentation product containing 3-phenyllactate in increasing the expression of genes related to mitochondrial respiratory chain complex II and V in fibroblasts; the genes related to mitochondrial respiratory chain complex II and V include: succinate dehydrogenase complex subunit A (SDHA), succinate dehydrogenase complex subunit B (SDHB), ATP synthase subunit α (ATP5A), ATP synthase subunit β (ATP5B), mitochondrial ribosomal protein L23 (MRPL23), and mitochondrial ribosomal protein S3 (MRPS3); B6) Use of 3-phenyllactate or a fermentation product containing 3-phenyllactate in the preparation of a product for increasing the expression of genes related to mitochondrial respiratory chain complexes II and V in fibroblasts; the genes related to mitochondrial respiratory chain complexes II and V include: succinate dehydrogenase complex subunit A (SDHA), succinate dehydrogenase complex subunit B (SDHB), ATP synthase subunit α (ATP5A), ATP synthase subunit β (ATP5B), mitochondrial ribosomal protein L23 (MRPL23), and mitochondrial ribosomal protein S3 (MRPS3).

7. A skin care product, characterized in that: The invention relates to a fermentation product comprising the 3-phenyllactate according to claim 1 or comprising the 3-phenyllactate.

8. The skin care product according to claim 7, characterized in that The skin care product includes at least one of lotion, emulsion, base lotion, essence, facial mask, sunscreen, face cream, eye cream, hand cream or body cream.

9. The skin care product according to claim 8, characterized in that The facial mask is a patch-type facial mask or a smear-type facial mask; Alternatively, the essence is essence water, essence oil or essence gel.

10. The skin care product according to claim 7, characterized in that The skin care product also includes cosmetically acceptable excipients; Preferably, the auxiliary material is one or more of a solvent, a thickener, a humectant, a film former, a liposome, a preservative, a colorant, a pH adjuster and a flavor.